BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients
with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in …

The discovery of activating mutations in the serine/threonine (S/T) kinase BRAF followed by
a wave of follow-up research manifested that the MAPK-pathway plays a critical role in …

Mitogen-activated protein kinase (MAPK) pathway has an important role in normal cells and
can be activated under physiological conditions. MAPK pathway activation is a fundamental …

The discovery of activating BRAF mutations in melanomas has led to the investigation of
small molecular inhibitors targeting BRAF mutation and MEK, a downstream protein within …

BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …

About half of all cutaneous melanomas harbor activating mutations in the BRAF oncogene.
Dependence on this pathway makes the tumors vulnerable to BRAF (and downstream MEK) …

Historically, patients with advanced cutaneous melanoma have a poor prognosis and limited
treatment options. The discovery of selective v-raf murine sarcoma viral oncogene homolog …

Activating mutations in the BRAF gene are among the most prevalent kinase mutations in
human cancer. BRAF mutations are most frequent in patients with melanoma where they …

Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with
advanced BRAFV600 mutated melanoma has shown objective tumor responses in …

Introduction: BRAF inhibition alone has achieved unprecedented efficacy results in patients
affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that …